Minireview: A novel pathway of prostacyclin signaling - Hanging out with nuclear receptors

Endocrinology

Volumn 143, Issue 9, 2002, Pages 3207-3210

  Hyunjung, Lim ^a   Dey, Sudhansu K ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; CARBACYCLIN; CELL NUCLEUS RECEPTOR; CELL SURFACE RECEPTOR; CICAPROST; FATTY ACID; FATTY ACID DERIVATIVE; ICOSANOID; ILOPROST; LIPOXYGENASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTACYCLIN RECEPTOR; PROSTACYCLIN SYNTHASE; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN SYNTHASE; UNCLASSIFIED DRUG; CELL RECEPTOR; CYCLOOXYGENASE 2; ISOENZYME; MEMBRANE PROTEIN; PROSTAGLANDIN RECEPTOR; PTGS2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ANIMAL CELL; APOPTOSIS; CELL SURFACE; COLORECTAL CANCER; DISEASE PREDISPOSITION; HYPOLIPEMIA; LIGAND BINDING; MOLECULAR CLONING; MOUSE; NIDATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RECEPTOR BINDING; SHORT SURVEY; SIGNAL TRANSDUCTION; ANIMAL; CELL NUCLEUS; COLORECTAL TUMOR; FEMALE; HUMAN; INTRACELLULAR MEMBRANE; METABOLISM; MOUSE MUTANT; PREGNANCY; REVIEW; ULTRASTRUCTURE;

ANIMALS; CELL NUCLEUS; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; EMBRYO IMPLANTATION; EPOPROSTENOL; FEMALE; HUMANS; INTRACELLULAR MEMBRANES; ISOENZYMES; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; PREGNANCY; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, EPOPROSTENOL; RECEPTORS, PROSTAGLANDIN; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 0036716140     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2002-220159     Document Type: Short Survey

References (53)

1. Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation
2. Human arterial and venous tissues generate prostacyclin (prostaglandin X), a potent inhibitor of platelet aggregation
3. Pharmacodynamic profile of prostacyclin
4. Cyclooxygenases: Structural, cellular, and molecular biology
5. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
6. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids
7. 2
8. Colocalization of prostacyclin synthase with prostaglandin H synthase-1 (PGHS-1) but not phorbol ester-induced PGHS-2 in cultured endothelial cells
9. Eighth Gaddum Memorial Lecture
10. Carbacyclin - A potent stable prostacyclin analogue for the inhibition of platelet aggregation
11. Identification and characterisation of a prostacyclin-like receptor in bovine coronary arteries using a specific and stable prostacyclin analogue, ciloprost, as radioactive ligand
12. Pharmacological profile of a novel carbacyclin derivative with high metabolic stability and oral activity in the rat
13. 2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium
14. 2 synthase in the endothelium and smooth muscle of bovine aorta
15. 2 synthase antigen in smooth muscle cells
16. Subcellular localization of prostaglandin endoperoxide H synthases-1 and -2 by immunoelectron microscopy
17. cDNA cloning of a mouse prostacyclin receptor. Multiple signaling pathways and expression in thymic medulla
18. Internalization and sequestration of the human prostacyclin receptor
19. Functional and ligand binding studies suggest heterogeneity of platelet prostacyclin receptors
20. Characterization of the prostanoid receptors mediating constriction and relaxation of human isolated uterine artery
21. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor
22. Differential activation of peroxisome proliferator-activated receptors by eicosanoids
23. Activation of gene transcription by prostacyclin analogues is mediated by the peroxisome-proliferators-activated receptor (PPAR)
24. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta
25. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors
26. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors
27. Nuclear hormone receptor coregulators in action: Diversity for shared tasks
28. 4 pathway to inflammation control
29. 2 is a ligand for the adipocyte determination factor PPARγ
30. 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation
31. Nuclear receptors and lipid physiology: Opening the X-files
32. COX-2 compensation in the uterus of COX-1 deficient mice during the pre-implantation period
33. Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARδ
34. Multiple female reproductive failures in cyclooxygenase 2-deficient mice
35. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
36. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
37. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs
38. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor δ in colorectal cancer
39. Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-δ in human endometrial adenocarcinoma
40. Peroxisome proliferator-activated receptor δ is upregulated during vascular lesion formation and promotes post-confluent cell proliferation in vascular smooth muscle cells
41. Prostacyclin-dependent apoptosis mediated by PPARδ
42. Critical roles of PPARβ/δ in keratinocyte response to inflammation
43. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β(δ)
44. Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer
45. Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)α and PPARβ mutant mice
46. Alterations of peroxisome proliferator-activated receptor δ activity affect fatty acid-controlled adipose differentiation
47. Peroxisome-proliferator-activated receptor δ mediates the effects of long-chain fatty acids on post-confluent cell proliferation
48. Expression of peroxisome proliferator-activated receptor PPARδ promotes induction of PPARγ and adipocyte differentiation in 3T3C2 fibroblasts
49. The peroxisome proliferator-activated receptor δ promotes lipid accumulation in human macrophages
50. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport
51. Activation of peroxisome proliferator-activated receptors (PPARs) by their ligands and protein kinase A activators
52. Peroxisome proliferator-activated receptor δ (PPARδ)-mediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signaling
53. Prostacyclin IP receptor up-regulates the early expression of C/EBPβ and C/EBPδ in preadipose cells